NeuroSense Therapeutics Ltd. has reported exploratory biomarker findings from its Phase 2 RoAD study of PrimeC in Alzheimer’s disease, pointing to changes across proteins associated with tau pathology, amyloid processing, inflammation, oxidative stress and other neurodegenerative mechanisms. The company believes the findings provide early evidence that its fixed-dose combination therapy may engage biological pathways relevant to Alzheimer’s disease.
The update offers NeuroSense a basis for planning a larger clinical study, but it should not be mistaken for evidence that PrimeC slows memory loss, preserves daily functioning or modifies the course of Alzheimer’s disease. The RoAD trial enrolled only eight participants, and the latest analysis relied on complete cerebrospinal-fluid and plasma sample sets from three people who reached the 12-month follow-up.
That gap between an interesting biological observation and a clinically meaningful result defines the real PrimeC story. NeuroSense has identified signals worth investigating, but it remains far from proving that combining ciprofloxacin and celecoxib can become an effective or practical long-term treatment for Alzheimer’s disease.
What did NeuroSense actually observe in the Phase 2 RoAD Alzheimer’s study?
RoAD was designed as a randomised, double-blind and placebo-controlled proof-of-concept study examining the safety, tolerability and biomarker effects of PrimeC in people with Alzheimer’s disease. Clinical outcome measurements were included, but the study was exploratory and was not powered to determine whether the treatment improved cognition or everyday function.
NeuroSense said the plasma analysis revealed changes involving brain-derived total tau, phosphorylated tau and the amyloid-beta 42-to-40 ratio. These proteins are closely associated with Alzheimer’s biology and are increasingly used to diagnose disease, classify patients and track biological changes during drug development.
The company also observed changes involving alpha-synuclein and TAR DNA-binding protein 43, commonly known as TDP-43. Alpha-synuclein is primarily associated with Parkinson’s disease and dementia with Lewy bodies, while TDP-43 is strongly linked to amyotrophic lateral sclerosis and certain forms of frontotemporal degeneration.
Both proteins can also appear as co-pathologies in people diagnosed with Alzheimer’s disease. Their presence may contribute to more rapid decline or greater clinical complexity, which supports the broader idea that dementia frequently involves several interacting forms of abnormal protein accumulation rather than amyloid alone.
Additional changes were reported in biomarkers connected with inflammation, oxidative stress, protein homeostasis and neurodegeneration. NeuroSense said the direction of these changes was consistent with PrimeC’s proposed multi-target mechanism and with biomarker findings previously observed in its amyotrophic lateral sclerosis programme.
The results remain descriptive. The company has not shown that the reported changes were statistically robust, replicated across a meaningful population or associated with slower cognitive decline.
Why does the three-patient sample make the Alzheimer’s findings difficult to interpret?
Small proof-of-concept studies can help researchers decide whether a biological idea deserves further investigation. They can also produce findings that disappear when tested in larger and more diverse populations.
The latest RoAD analysis is especially preliminary because complete cerebrospinal-fluid and plasma samples were available from only three participants at the required timepoints. With such a small sample, one unusual patient can materially influence the overall pattern.
It is also difficult to account for natural variation. Alzheimer’s biomarkers can change over time because of disease progression, age, other medical conditions, laboratory variability and medications unrelated to the experimental treatment.
Randomisation and placebo control ordinarily help separate a drug effect from background variation. Those protections become much less informative when the analysed population is extremely small and when the distribution of treated and placebo participants within the available sample is insufficient to support meaningful comparisons.
The findings therefore cannot establish dose response, identify which patients may benefit or determine whether the observed biological changes are reproducible. They also cannot reliably distinguish a true PrimeC effect from chance.
NeuroSense acknowledged these limitations and said the study should inform a future adequately powered trial. That measured interpretation is important because language such as positive biomarker findings can sound more conclusive than the underlying data justify.
The appropriate conclusion is that PrimeC may be affecting biological pathways relevant to neurodegeneration. Whether those effects are genuine, sustained and clinically useful remains unknown.
Can biomarker movement predict whether patients will experience slower cognitive decline?
Biomarkers have become central to Alzheimer’s research. Blood and cerebrospinal-fluid measurements can help confirm the presence of amyloid and tau pathology, select appropriate patients for trials and measure how a treatment affects its intended biological target.
However, a biomarker response is not automatically equivalent to clinical benefit. A drug may lower or alter a disease-associated protein without producing a meaningful difference in memory, reasoning, communication or independence.
The regulatory standard depends on the development stage, the patient population and how well a biomarker has been shown to predict patient benefit. For symptomatic Alzheimer’s disease, clinical studies generally need to evaluate both biological changes and outcomes that reflect how patients think, function or manage everyday activities.
PrimeC’s reported signals are even earlier than the established amyloid endpoints used in large antibody trials. NeuroSense reported directional changes across several proteins and pathways rather than demonstrating a validated surrogate endpoint tied to a predetermined clinical benefit.
That breadth may support the company’s multi-target theory, but it also makes interpretation more complicated. When a treatment changes many biomarkers, researchers must determine which changes are central to the mechanism, which are secondary and which may simply represent biological noise.
A larger study will need prospectively defined hypotheses, standardised testing methods and clear statistical controls. It should also establish whether biomarker changes correlate with cognitive or functional outcomes over a clinically meaningful period.
Until that happens, the RoAD findings remain a biological signal rather than evidence of disease modification.
Why is NeuroSense using two established drugs instead of developing a new molecule?
PrimeC is an extended-release oral formulation combining ciprofloxacin and celecoxib. Ciprofloxacin is an antibacterial drug from the fluoroquinolone class, while celecoxib is a selective cyclooxygenase-2 inhibitor commonly used for pain and inflammatory conditions.
NeuroSense is not developing the combination primarily to treat infection or relieve pain. The company believes the two active ingredients may act together on pathways involving inflammation, iron accumulation, impaired RNA regulation, oxidative stress and abnormal protein processing.
This repurposing strategy offers potential advantages. Both components have extensive human-use histories, established manufacturing processes and known pharmacological characteristics. Using familiar active ingredients may reduce some uncertainty compared with developing a completely new chemical entity.
A fixed-dose, extended-release formulation may also create intellectual property and pharmacokinetic differentiation. NeuroSense can attempt to optimise exposure, dosing frequency and the interaction between the two compounds rather than merely administering conventional tablets together.
However, familiarity does not remove development risk. A drug used briefly for infection may have a different risk profile when given chronically to older adults with neurodegenerative disease. The safety of the exact PrimeC formulation, dose and duration must be established within the intended population.
Repurposing also creates a demanding evidentiary burden. Because both ingredients are already available, NeuroSense must show that its proprietary combination produces a benefit that cannot be achieved through ordinary clinical use and that the value is sufficient to justify regulatory approval, reimbursement and intellectual-property protection.
Could long-term ciprofloxacin and celecoxib exposure become a major development obstacle?
Safety may become one of the most important questions in any larger Alzheimer’s programme. People with Alzheimer’s disease are often older and may have cardiovascular disease, kidney impairment, gastrointestinal vulnerability, mobility limitations and complex medication regimens.
Ciprofloxacin carries recognised risks associated with the fluoroquinolone class, including tendon injury, peripheral neuropathy and central nervous system effects. The relevance of these risks will depend on PrimeC’s dose, exposure and treatment duration, but they cannot be dismissed merely because the ingredient is already approved.
Celecoxib and other nonsteroidal anti-inflammatory drugs carry warnings involving cardiovascular and gastrointestinal events. Older patients may be especially vulnerable, particularly when they have existing cardiovascular risk or use anticoagulants and other interacting medications.
NeuroSense reported that the small RoAD study produced no serious adverse events or unexpected safety signals. That finding is reassuring within the limited exposure available, but three fully analysed patients and eight enrolled participants cannot characterise uncommon or cumulative risks.
A larger study will require careful cardiovascular, neurological, renal and gastrointestinal monitoring. Researchers will also need to establish whether any safety burden is acceptable relative to the magnitude of clinical benefit.
This comparison matters because Alzheimer’s treatments may be administered for extended periods. A modest biomarker effect would be difficult to justify if long-term treatment introduced material risks in a medically vulnerable population.
PrimeC’s development pathway therefore depends not only on whether the combination changes disease biology, but on whether it can do so safely enough for chronic use.
Does targeting several neurodegenerative pathways offer an advantage over amyloid-focused drugs?
The Alzheimer’s treatment landscape has increasingly validated amyloid as a therapeutic target, but approved amyloid antibodies provide limited slowing of decline rather than restoration of lost cognitive function. They also require careful patient selection, repeated infusions or injections, imaging surveillance and management of treatment-related risks.
NeuroSense’s strategy is based on the view that Alzheimer’s disease results from several interacting processes, including abnormal protein accumulation, inflammation, oxidative stress, iron dysregulation and impaired cellular maintenance.
A multi-target oral therapy could theoretically complement or provide an alternative to treatments focused on one pathological protein. It might also be relevant to patients with mixed disease involving amyloid, tau, alpha-synuclein or TDP-43.
That idea is scientifically attractive because many older patients do not have a single pure pathology. Autopsy and biomarker studies frequently identify overlapping forms of protein accumulation and vascular disease.
The difficulty is proving which mechanism matters. A therapy designed to influence many pathways may produce broad biomarker activity without exerting a sufficiently strong effect on any one disease driver.
Multi-target development can also complicate dose selection and regulatory evaluation. Researchers must explain how the components interact, why the combination is necessary and which measurements best demonstrate that the mechanism is working.
PrimeC could eventually differentiate itself through convenience and biological breadth, but those theoretical advantages have not yet been demonstrated in Alzheimer’s patients.
How does the Alzheimer’s programme fit with NeuroSense’s more advanced ALS strategy?
PrimeC’s principal development history has been in amyotrophic lateral sclerosis. NeuroSense has reported clinical and biomarker findings from the Phase 2b PARADIGM programme and has been preparing for a potential Phase 3 pathway.
The Alzheimer’s study appears to extend the same mechanistic thesis into a second neurodegenerative condition. The company believes inflammation, abnormal RNA regulation, oxidative stress and protein misfolding overlap across amyotrophic lateral sclerosis, Alzheimer’s disease and other neurological disorders.
This platform approach could create significant value if the mechanism proves transferable. A single formulation capable of addressing shared neurodegenerative pathways might support several indications and make the development programme more attractive to potential partners.
It could also stretch the company’s resources. Alzheimer’s trials are expensive, lengthy and operationally demanding. They require larger populations, specialised cognitive assessments, biomarker confirmation and extended follow-up.
NeuroSense must decide whether to fund Alzheimer’s development independently, seek a licensing partner or maintain the programme as an early scientific option while prioritising amyotrophic lateral sclerosis.
The latest findings may improve the programme’s partnering narrative because they provide human biomarker observations. They are unlikely to support a major late-stage investment without replication in a larger trial.
The company’s next Alzheimer’s study must therefore be designed not only to answer a scientific question, but to create evidence strong enough to attract capital or strategic collaboration.
What must the next PrimeC Alzheimer’s trial prove to become clinically meaningful?
The next study should enrol a substantially larger and clearly defined population with biomarker-confirmed Alzheimer’s disease. Patient stage will matter because treatments may perform differently in mild cognitive impairment, early dementia and more advanced disease.
NeuroSense must identify a dose that produces the intended biological exposure while remaining suitable for long-term use. The study should include predetermined biomarker endpoints and validated measures of cognition and daily functioning.
Researchers will need to demonstrate that any biomarker changes differ meaningfully from placebo rather than merely moving in the direction predicted by the mechanism. Statistical methods should account for multiple biomarkers to reduce the risk of finding apparently positive results by chance.
Clinical outcomes should measure whether patients decline more slowly over time. Even when a study is not large enough to prove definitive efficacy, consistency between biomarker effects and clinical trends would strengthen the development case.
Safety monitoring must reflect the known profiles of ciprofloxacin and celecoxib as well as potential risks created by their combined and extended use. Older adults with cardiovascular, gastrointestinal, neurological and renal comorbidities should be represented appropriately.
The trial should also clarify whether PrimeC is intended as a standalone therapy or could eventually be combined with amyloid-targeting treatments. Combination use might broaden its relevance, but it would add further safety and development complexity.
Most importantly, the next trial must produce interpretable data. Another very small exploratory study could generate additional hypotheses without moving the programme materially closer to approval.
What does NeuroSense’s stock performance reveal about investor confidence in PrimeC?
NeuroSense Therapeutics shares were trading near $0.76 around June 25, leaving the stock close to the lower end of its 52-week range of approximately $0.63 to $2.19.
The shares were down roughly 5 percent over five trading sessions and approximately 13 percent from their May 26 closing level. They remained about 65 percent below the 52-week high, suggesting that investors continued to assign substantial development and financing risk to the company.
The biomarker announcement did not create a sustained revaluation. That restrained response appears consistent with the extremely limited Alzheimer’s dataset and the market’s greater focus on the company’s amyotrophic lateral sclerosis strategy.
NeuroSense reported only about $0.2 million in cash at the end of 2025. The company subsequently raised additional capital and established financing flexibility, but further clinical development is likely to require more funding.
This creates dilution risk for shareholders. A larger Alzheimer’s trial would add to the cost of the amyotrophic lateral sclerosis programme, regulatory work, manufacturing and general operations.
For a micro-cap biotechnology company, positive scientific signals can improve access to capital without eliminating dependence on capital markets. The value of the RoAD findings may therefore lie partly in supporting partnership discussions or future financing rather than producing immediate revenue potential.
Investor sentiment is likely to remain speculative until NeuroSense secures sufficient funding and provides a clear plan for a larger Alzheimer’s study.
Can PrimeC become a credible Alzheimer’s candidate after such a small proof-of-concept trial?
The RoAD findings provide NeuroSense with a reason to continue investigating PrimeC in Alzheimer’s disease. Observing changes across tau, amyloid, alpha-synuclein, TDP-43 and inflammatory pathways is consistent with the company’s argument that neurodegeneration requires a multi-target approach.
The findings are not sufficient to show that PrimeC treats Alzheimer’s disease. They cannot establish clinical benefit, determine statistical significance, characterise long-term safety or identify the patients most likely to respond.
The update should be treated as hypothesis-supporting evidence rather than a therapeutic breakthrough. The biological pattern is interesting because it crosses several neurodegenerative pathways, but the three-patient analytical sample prevents reliable conclusions.
NeuroSense’s next decision is therefore more important than the latest biomarker announcement. A well-designed, adequately funded trial could determine whether the signal is reproducible and whether it connects to slower cognitive decline.
A poorly powered follow-up would risk producing another ambiguous dataset and consuming scarce capital without resolving the central question.
PrimeC may ultimately benefit from combining known drugs, targeting several pathways and offering oral administration. Those features create a differentiated development concept, not a proven treatment.
The programme now needs evidence that moves beyond molecules in blood and cerebrospinal fluid. For patients and clinicians, the outcome that matters is whether PrimeC can preserve memory, independence and quality of life safely over time.
Key takeaways from NeuroSense’s PrimeC Alzheimer’s biomarker findings
- NeuroSense reported biomarker changes from the exploratory Phase 2 RoAD study that were directionally consistent with PrimeC’s proposed multi-target mechanism.
- The study enrolled eight participants, while only three completed the 12-month period with both cerebrospinal-fluid and plasma samples available for the reported analysis.
- The findings included changes involving tau, amyloid-beta, alpha-synuclein, TDP-43, inflammation and oxidative stress, but they do not establish clinical efficacy.
- PrimeC combines extended-release ciprofloxacin and celecoxib, creating a repurposing opportunity alongside important long-term safety questions.
- A future study will need a larger biomarker-confirmed population, placebo comparisons, clinical outcome measures and extensive safety monitoring.
- NeuroSense’s limited financial resources and low share price indicate that funding and shareholder dilution remain material development risks.
- The Alzheimer’s programme may support the company’s broader neurodegeneration platform, but amyotrophic lateral sclerosis remains PrimeC’s more advanced clinical opportunity.
